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Ne-(carboxymethyl)lysine in blood from maintenance hemodial-
ysis patients may contribute to dialysis-related amyloidosis.
Background. Recent studies demonstrated not only that ad-
vanced glycation end product could be found in amyloid tissue
from patient with dialysis related amyloidosis, but also that
amyloid b2-microglobulin was modified with Ne-(carboxy-
methyl)lysine (CML). We wanted to determine if CML could be
a biomarker in these patients.
Methods. To raise polyclonal anti-carboxymethyllysine anti-
body, human serum albumin was carboxymethylated by glyoxylic
acid and was immunized to rabbits as antigen. Carboxymethyll-
ysine-hemoglobin (CML-Hb) levels were measured by the dot
blotting method using this antibody.
Results. The levels of CML-Hb were 6.68 6 3.10 nmol CML/mg
Hb in nondiabetic hemodialysis patients (N 5 70), 6.39 6 3.43
nmol CML/mg Hb in diabetic hemodialysis patient (N 5 21), and
3.13 6 0.88 nmol CML/mg Hb in 47 healthy volunteers. For
clinical signs of dialysis-related amyloidosis, 70 nondiabetic hemo-
dialysis patients were scored according Gejyo’s criteria. The
CML-Hb levels in patients with a high amyloid score as well as a
low amyloid score were significantly higher than in patients with
negative amyloid score (8.89 6 3.53 nmol CML/mg Hb, 7.28 6
2.32 nmol CML/mg Hb vs. 5.11 6 2.09 nmol CML/mg Hb, P ,
0.001, P , 0.05). Furthermore, the CML-Hb levels correlated
significantly with serum values of the methylguanidine over cre-
atinine ratio and hyaluronate.
Conclusions. We suggest that CML-Hb is increased in blood
from patients on maintenance hemodialysis and is thus a potential
biomarker of oxidative damage in these patients. Moreover,
CML-modification of protein may play a pathogenic role in the
development of dialysis related amyloidosis.
The importance of advanced glycation end products
(AGE), which are late products of the Maillard reaction, in
the life sciences has become increasingly acknowledged
over the last 15 years [1–3]. However, details of their
characteristics, mechanism(s) of production and function in
vivo remain to be precisely elucidated. Among the various
heterogeneous forms of AGE, two molecular forms, pen-
tosidine and carboxymethyllysine (CML), are of particular
interest in the clinical setting of chronic oxidative stress
(such as uremia), because both of these molecules are
produced by the combined process of glycation and oxida-
tion [4].
With CML, recent in vitro studies showed that it is
produced through an alternative route via a highly reactive
intermediate, a-dicarbonyl, rather than through an ad-
vanced progression of the Maillard reaction, and it is
suggested that this alternative route might be as important
as the termination of the Maillard reaction in vivo [5]. In
addition, it has been confirmed that the participation of a
radical molecule is essential in this short production route
[6]. Wells-Knecht et al identified glyoxal as the dicarbonyl
compound formed in autoxidation of glucose, and also found
that carboxymethylated RNase is formed by glyoxal [7].
While Ne-(carboxymethyl)lysine (CML) was first re-
ported in vivo in 1975 [8], was not until 1986, when Ahmed
et al [9] reported CML formed by a radical reaction from
fructose-lysine, that CML was recognized as an intriguing
AGE in vivo. Later, Reddy et al [10] and then Ikeda et al
[11] found that the epitope responsible for the reaction
with the anti-AGE serum consisted mainly of the CML
structure. A more recent study confirmed that, in patients
on maintenance hemodialysis (HD), b2-microglobulin
from amyloid tissues was modified with CML [12], suggest-
ing that CML is crucially involved in the development of
dialysis-related amyloidosis. In patients with chronic renal
failure (CRF), few data on the direct determination of
CML-protein in the systemic circulation have been re-
ported, despite several reports having confirmed remark-
ably increased circulating levels of immunoreactive AGE-
protein or pentosidine [13–17 ].
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In this report, we evaluated the specificity of our anti-
serum prepared against CML-protein and measured CML-
hemoglobin (CML-Hb) levels in the systemic circulation of
91 HD patients, including 21 diabetic patients, and in 7
pre-dialysis patients with CRF. Furthermore, the circulat-
ing CML-Hb level was analyzed by comparison with the
clinical features of dialysis-related amyloidosis to deter-
mine the clinical significance of CML-Hb in dialysis-related
amyloidosis, which is unique to dialysis medicine. To our
knowledge, the data presented herein are the first on the
circulating levels of CML-protein in a sufficient number of
patients maintained on hemodialysis to discuss the rele-
vance of CML in the development of dialysis-related
amyloidosis.
METHODS
Preparation of standard Ne-carboxymethyllysine
Ne-carboxymethyllysine (CML) was prepared as de-
scribed previously [9]. In brief, CML was obtained by
incubating 0.1 M Na-formyllysine and 0.1 M iodoacetic acid
in 0.2 M phosphate buffer (pH 10) for 40 hours at room
temperature. Unreacted iodoacetate was discarded by ad-
dition of NH4OH, followed by continued incubation over-
night. After phosphate and iodide were removed by Dowex
1-X8, the eluate was concentrated by rotary evaporation.
The products were deformylated by hydrolysis in 2 N HCl
for 30 minutes at 95°C. CML was isolated by ion exchange
chromatography on Dowex 50-X8.
The identity of CML was confirmed by nuclear magnetic
resonance (NMR) and mass spectrometry (Fig. 1).
Chemical modification of proteins or polylysine
Carboxymethylated human serum albumin (CML-HSA)
was prepared by incubating HSA (fraction V, 1 mg; Sigma
Chemicals, St. Louis, MO, USA) in 1 ml of 0.1 M borate
buffer, pH 9.0, containing glyoxylic acid (0.25 M) and
sodium cyanoborohydride (1 mg) for 12 hours at 0°C (Fig.
2) [18]. CML-Hb or carboxymethylated polylysine (CM-
polylysine) was also prepared from Hb (fraction V, 1 mg;
Sigma Chemicals) or polylysine (Wako Chemical Co.,
Osaka, Japan) in the same manner.
The CML content of CML-HSA, CML-Hb, or CM-
polylysine was measured by amino acid analysis following
hydrolysis of the modified proteins or polylysine in 6 N HCl
for 24 hours at 110°C. Amino acid analysis was perfomed
on a Hitachi amino acid analyzer (Model 835, Hitachi,
Tokyo, Japan). The CML content in CML-HSA, CML-Hb
or CM-polylysine was approximately 99 nmol CML/mg
HSA, 11 nmol CML/mg Hb or 2000 nmol CML/mg poly-
lysine, respectively.
Preparation of polyclonal anti-CML antibody
To raise the anti-CML antibody, 1.0 mg of CML-HSA in
50% Freund’s complete adjuvant was injected into a rabbit.
The rabbit was subjected to booster two weeks later with
half the amount of CML-HSA in 50% Freund’s incomplete
adjuvant, followed by four additional booster injections
every two weeks. After confirming the rise in antibody
levels against CML-HSA six weeks later, the antibody
serum was collected and passed over a column (1.5 3 10
cm) of Affi-Gel 15 (BIO-RAD, Hercules, CA, USA)
coupled with HSA. The nonabsorbed fraction was further
passed through another HSA-immobilyzed column to com-
pletely remove the antibody fraction reactive to HSA.
Biotin labeling of anti-CML-protein antibody
Biotinylation of anti-CML antibody was performed using
a Protein Biotinylation System (Gibco BRL, Gaithersburg,
MD, USA). Seven milliliters of the antibody solution (1.5
mg/ml) in 0.05 M sodium carbonate (pH 9.0) were pre-
pared. Next, 26 ml of e-caprolyamidobiotin-N-hydroxy suc-
cinimide ester (50 mg/ml) in dimethylformamide were
prepared, and then added to the antibody solution. After
mixing well, the solution was incubated at room tempera-
ture for one hour. After 920 ml of 1 M NH4Cl had been
added to the solution to stop the biotinylation reaction, the
biotinylated antibody solution was loaded into the desalting
column.
Western blotting
Hemolysates were separated by sodium dodecyl sulfate-
polyacrylamide gel electrophoresis (SDS-PAGE) at 18 mA
(constant) for 1.5 hours with 4 to 20% gradient gel. After
transfer to a polyvinylidene difuluoride (PVDF) membrane
(BIO-RAD) for one hour at 10 V (constant), the mem-
brane was incubated with 1% bovine serum albumin (BSA,
sigma) for one hour, followed by three three-minute washes
with phosphate-buffered saline (PBS) containing 0.05%
Tween 20 (wash buffer). The membrane was then incu-
bated with biotin labeled anti-CML-protein (0.01 mg/ml) in
PBS. For the development phase, the membrane was
washed three times in a wash buffer, and then incubated
with 30 minutes. The membrane was again washed three
times with the wash buffer and incubated with an ECL
reagent (Amersham, Buckinghamshire, UK). The mem-
brane was placed in the film cassette in which a sheet of
X-ray film was placed on top of the membrane. After
closing the casette and exposure, the X-ray film was
developed.
Dot blotting
Anticoagulated blood was collected in tubes containing
EDTA-2K, and hemolyzed with 20 vol of distilled water on
ice. The hemolysate was stored at 280°C until assay.
CML-protein levels were measured by a dot blotting
technique, essentially as described by Glassy and Cleveland
[19]. After thawing, the hemolysates were diluted 1000-fold
with 20 mM PBS, then 0.1 ml aliquots were applied to the
PVDF membrane in each well of a dot blotting apparatus
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(Bio Dot; BIO-RAD). The membrane was immersed at
room temperature for one hour in PBS (pH 7.4) containing
10% skim milk, and then, 5 ml of PBS containing 1 mg/ml
of biotin-labeled anti-CML antibody was reacted at room
temperature for one hour. After the reaction, the mem-
brane was washed three times with wash buffer, and soaked
by shaking in 5 ml of PBS containing an avidin-peroxidase
labeled biotin complex (Vectastain ABC kit; Vector) at
room temperature for 30 minutes. Thereafter, the mem-
brane was washed three times repeatedly with the wash
buffer, and incubated in ECL reagent. Finally, the mem-
brane was placed in a film cassette and covered with a sheet
Fig. 1. The mass spectrum of Ne-(carboxymethyl)lysine (CML; A) and the 1H-NMR spectrum of CML (B). The mass spectrum was recorded on a
Hitachi M-2000 and 1H-NMR spectrum was recorded on a JEOL A-500 operating at 500 MHz. (A) m/z 297, m111glycerol; m/z 205, m11; m/z 160,
m-COO2; m/z 115, m-1 to 2COO2. (B) The sample solution was prepared by diluting with D2O.3-(trimethylsilyl)proionic-2,2,3,3-d4 acid, and sodium
salt was used as an internal standard.
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of X-ray film on its surface. After closing the cassette and
exposure to the X-rays, the film was developed. The
CML-protein level was measured by the intensity of the
luminescence on the film using a GS-363 molecular imager
(BIO-RAD) with synthesized CML-Hb (11 nmol CML/mg
Hb) as a standard.
Competitive ELISA
The cross reactivity with several related compounds was
performed by a competitive ELISA. Each well of the
microtiter plate was coated with CML-HSA containing 99
nmol CML/mg HSA as stated above. One hundred micro-
liters of the CML-HSA solution (1 mg/ml in carbonate
buffer, pH 9.8) was dispensed into each well and incubated
at 37°C for one hour. Competitors (CML-HSA, CML-Hb,
CM-polylysine, HSA, Hb or polylysine), 100 ml in PBS,
were mixed with 100 ml of biotin labeled anti-CML anti-
body (10 mg/ml) in phosphate buffered saline (PBS) and
stood at 37°C for one hour. The coating solution was
discarded, the wells were washed three times with PBS
containing 0.05% Tween 20 (wash buffer), and then
blocked with 300 ml of 1% skim milk for one hour at 37°C.
After washing again, 100 ml of each competitor specimen
mentioned above was then applied into the well and
incubated at 37°C for one hour. Each well was then washed
three times with wash buffer and was reacted with 100 ml of
PBS containing an avidin-biotin alkaline phosphatase com-
plex (Vectastain ABC kit, Vector) at 37°C for 30 minutes.
After washing, 100 ml of p-nitrophenyl phosphate solution
(BIO-RAD) was added to each well. The plate was gently
shaken at room temperature until an adequate color devel-
oped. The color development was stopped by the addition
of 100 ml of 0.5 N NaOH to each well. Consequently, the
absorbance at 405 nm was measured using a microplate
reader (BIO-RAD).
Patients
Seventy nondiabetic patients, aged from 20 to 84 years
(37 males, 33 females), 21 diabetic patients, aged from 40 to
73 years (12 males, 9 females) undergoing maintenance
hemodialysis (HD patients), and 7 pre-dialysis patients with
CRF due to nondiabetic renal disease (CRF patients; 5
males and 2 females, aged from 47 to 84 years) were
enrolled in this study. The duration of dialysis in HD
Fig. 2. Identification of Ne-(carboxymethyl)lysine (CML)-human serum albumin (HSA) as an antigen by amino acid analysis. CML contents of
modified protein was measured by amino acid analysis as described in the Methods section. Methionine (Met) and Isoleusine (Ilo) in acid hydrolysate
of HSA were eluted at 45.6 and 50.6 minutes, respectively (a). In the case of CML-HSA (b), a new peak (arrow) appeared with a retention time of 47.7
minutes, and the retention time corresponds to a retention time of standared CML showed in box figure, which is described in the Methods section.
Motomiya et al: Ne-(carboxymethyl)lysine-hemoglobin in hemodialysis patients1360
patients was from 3 to 258 months (126 6 65 months) in
nondiabetic HD patients and from 3 to 168 months (57 6
53 months) in diabetic HD patients.
Laboratory data related to dialysis-related amyloidosis
Measurements of serum b2-microglobulin (b2m), meth-
ylguanidine (MG) and hyaluronate (HA) were carried out
by a radioimmunoassay (RIA), an enzymic method [20],
and a sandwich binding protein assay (SBPA), respectively.
The standard levels of serum MG and HA were , 4.6
mg/dl and , 50 ng/ml, respectively.
Statistical analysis
Data were expressed as mean 6 SD. Scheffe’s multiple
comparison test was used to compare between means, and
a correlation was determined by Pearson’s correlation




The specificity of anti-CML antibody was examined by
competitive ELISA. As shown clearly in Figure 3, dose-
dependent inhibition was confirmed in CML-Hb and CM-
polylysine as well as in CML-HSA, while no inhibition was
recognized in noncarboxymethylated Hb, polylysine or
HSA even at 100 mg per well, demonstrating the specificity
of the anti-CML antibody used in this study.
Identification of the major CML-protein in blood
To identify the major CML-protein, blood obtained from
a normal subject or diabetic patient was fractionated into
erythrocytes lysate, leukocytes lysate and platelet rich
plasma. In dot blotting (Fig. 4A), the anti-CML antibody
reacted with erythrocyte lysate obtained from normal sub-
ject, whereas the antibody did not react with the leukocyte
lysate nor platelet rich plasma. These data support the
notion that CML-protein is mainly present in erythrocyte
lysate. Furthermore, it is clear that anti-CML antibody
strongly reacts with hemoglobin derived from normal eryth-
rocyte lysate by Western blotting (Fig. 4B). These results
suggest that hemoglobin is mainly carboxymethylated in
blood.
Standard curve of the dot blotting assay for CML-Hb
To test whether the CML-protein could be measured by
dot blotting, we examined the immunological reaction of
anti-CML polyclonal antibody with synthesized CML-Hb.
In dot blotting using the antibody (Fig. 5), the lumines-
cence intensity increased in proportion to amount of the
CML-Hb added to the well. A similar result was obtained
by Hb from normal subjects or patients with hemodialysis
(data not shown).
Reproducibility studies of Hb from normal subjects or
patients with hemodialysis showed intra-assay and inter-
assay coefficient of variances of 2.9 to 4.9% and 7.1 to
9.2%, respectively (Table 1).
Circulating CML-Hb levels
The CML-Hb levels were determined in 47 healthy
volunteers (21 to 46 years of age, mean 32 6 five years) and
ranged from 2.02 to 5.52 nmol CML/mg Hb (3.13 6 0.88
nmol CML/mg Hb; Fig. 6). In 44 (93.6%) of the volunteers,
the CML-Hb level was less than 4.89 nmol CML/mg Hb, or
within the mean 6 2 SD. The CML-Hb levels were signifi-
cantly higher in HD patients and CRF patients with than in
healthy volunteers, ranging from 1.74 to 15.58 nmol
CML/mg Hb (mean 6.68 6 3.10 nmol CML/mg Hb) in
nondiabetic HD patients, from 1.91 to 16.30 nmol CML/mg
Hb (6.39 6 3.43 nmol CML/mg Hb) in diabetic HD
patients, and from 1.94 to 7.83 nmol CML/mg Hb (4.16 6
2.21 nmolCML/mgHb) in CRF patients (Fig. 6).
A remarkable variation among our patients was recog-
nized, and in 26 (37.1%) nondiabetic HD patients the levels
were less than 4.89 nmol CML/mg Hb, which corresponded
with the upper limit in healthy volunteers (mean 6 2 SD).
There were no differences in the CML-Hb levels between
nondiabetic HD and diabetic HD patients. Moreover, the
CML-Hb levels in diabetic HD patients failed to show a
significant correlation with the HbA1c value (r 5 20.337,
P 5 0.135, NS).
Duration of dialysis and the CML-Hb level
Although a significant correlation was found between
dialysis duration and CML-Hb levels in nondiabetic HD
patients (r 5 0.293, P , 0.02), the CML-Hb level in 62
patients (excluding 8 patients who were in the early phase
less than three years of hemodialysis) did not correlate with
hemodialysis duration.
Fig. 3. Specificity of polyclonal anti-CML antibody to CML-protein
adducts or CM-polylysine by competitive ELISA. Dose dependent inhibi-
tions with CML-HSA (f), CML-Hb () and CM-polylysine(F) were
shown, but no reactions were recognized with HSA (M), Hb (), and
polylysine (E).
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Carpal tunnel syndrome and destructive
spondyloarthropathy
Among 70 nondiabetic HD patients, 22 had clinical signs
of carpal tunnel syndrome (CTS) and 17 of that subgroup
had a history of surgery for CTS. The mean CML-Hb level
in patients with CTS was significantly higher than that in
patients without CTS (7.79 6 3.54 nmol CML/mg Hb vs.
6.17 6 2.76 nmol CML/mg Hb; P , 0.05; Fig. 7). Never-
theless, many cases were found to be overlapped with each
other.
Destructive spondyloarthropathy (DSA) was assessed by
magnetic resonance imaging (MRI) as well as by X-ray film
on the cervical and lumbar portions of the spine. Compat-
ible findings were noted in 16 nondiabetic HD patients, 14
of whom had been on hemodialysis for 120 months or
more. In contrast to data with the CTS patients, the
CML-Hb levels in the 16 patients with DSA averaged
7.20 6 2.44 nmol CML/mg Hb, and were not significantly
higher than the value of the 54 patients without DSA, that
is, 6.53 6 3.27 nmolCML/mgHb.
Fig. 4. (A) Reactivity of fractionated blood by dot blotting with polyclonal anti-CML antibody. Bloods were analyzed by dot blotting method as
described in the Methods section. Venous blood, erythrocytes lysate, leukocytes lysate and platelet rich plasma derived normal subject were absorbed
to PVDF membrane, respectively, excess sites on the membrane were blocked by 10% skimmilk. (B) Western blotting of erythrocytes lysate with
polyclonal anti-CML antibody. Human Hb on the market (sigma; lane 2), synthesized CML-Hb (34.4 nmol CML/mg Hb; lane 3) and erythrocytes lysate
obtained from normal subject (lane 4) were subjected to SDS-PAGE, electroblotting, and then blots were reacted with anti-CML antibody. Size marker
is shown in lane 1.
Fig. 5. Standard curve of synthesized CML-Hb in dot blotting. Curve
represents relative amount of anti-CML antibody binding to synthesized
CML-Hb (11 nmol CML/mg Hb) using dot blotting technique described in
the Methods section. Values are means 6 SD of 3 independent experi-
ments.
Table 1. Reproducibility of Ne-(carboxymethyl)lysine (CML)-








mean 6 SD CV% mean 6 SD CV%
Normal 1 2.18 6 0.09 4.0 2.21 6 0.20 9.2
Normal 2 3.56 6 0.10 2.9 3.45 6 0.27 7.8
Patient 1 8.16 6 0.24 3.0 8.12 6 0.58 7.1
Patient 2 10.89 6 0.53 4.9 10.53 6 0.91 8.6
Abbreviation CV is coefficient of variance.
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Amyloid score and CML-Hb level
The number of patients who had developed dialysis-
related amyloidosis was assessed in nondiabetic HD pa-
tients according to the study of van Ypersele de Strihou et
al [21]. In their report 34 nondiabetic HD patients had this
complication, 34 did not, and 2 were equivocal. In addition,
the amyloid score was counted in their patients by Gejyo’s
criteria [22]. The amyloid scores in the 2 equivocal patients
were 1 and 2, respectively. The CML-Hb level was signifi-
cantly higher in dialysis-related amyloidosis patients, rang-
ing from 3.44 to 15.61 nmol CML/mg Hb (mean 8.32 6 3.17
nmol CML/mg Hb), as compared to the patients without
that complication in whom the level ranged from 1.72 to
11.48 nmol CML/mg Hb (mean 5.16 6 2.13 nmol CML/mg
Hb).
The amyloid scores categorized all patients into three
subgroups: (1) negative patients (negative group, HD du-
ration 88 6 57 months, N 5 35) whose amyloid score was
1 or less; (2) low score patients (low group, HD duration
142 6 42 months, N 5 14) whose amyloid score was 2 or 3;
and (3) high score patients (high group, HD duration 181 6
42 months, N 5 21) whose amyloid score was 4 or more.
The CML-Hb level was 5.11 6 2.09 nmol CML/mg Hb in
the negative group, 7.28 6 2.32 nmol CML/mg Hb in the
low group and 8.89 6 3.53 nmol CML/mg Hb in the high
group, respectively (Fig. 8). As shown Figure 8, the
CML-Hb level in negative group was significantly lower
than that in the other two groups, but the difference
between low group and high group was not statistically
significant.
Serum levels of b2-microglobulin, methylguanidine and
CML-Hb
Serum levels of b2m varied from 15.4 mg/dl to 51.6 mg/dl
(36.1 6 7.6 mg/dl) and 19 patients had a high level of more
than 40 mg/dl. However, no correlation was found between
the CML-Hb level and the b2m level. By contrast, the
CML-Hb levels in all 77 patients, including CRF patients,
showed a significant correlation with the serum value of the
methylguanidine over creatinine ratio (MG/Cr; r 5 0.318
Fig. 6. Circulating levels of CML-Hb in healthy volunteers (N 5 47),
nonhemodialysis patients with chronic renal failure (CRF patients, N 5
7) and hemodialysis paients (nondiabetic HD patients, N 5 70, diabetic
HD patients, N 5 21). Significantly higher levels of CML-Hb were
recognized in these patient groups than in healthy volunteers (*P , 0.02,
**P , 0.0001). There were no differences between nondiabetic HD and
diabetic HD patients.
Fig. 7. Comparative study of circulating levels of CML-Hb in patients
with carpal tunnel syndrome [CTS(1), N 5 22] and in patients without
CTS [CTS(2), N 5 48]. The CTS(1) group included patients with history
of surgical therapy for CTS (, N 5 17) and with only clinial signs of CTS
(, N 5 5). A significant difference was showed between these two groups
(*P , 0.05).
Fig. 8. Comparative study of circulating levels of carboxymethylated
hemoglobin (CML-Hb) in patients with negative amyloid score (negative
group, N 5 35), with a low amyloid score (low group, N 5 14) and with a
high amyloid score (high group, N 5 21). The CML-Hb levels in both of
low group and high group were significantly higher than that in negative
group (*P , 0.05, **P , 0.001), but no significant difference was obtained
between the low group and high group (***NS).
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P , 0.01), which ranged from 0.55 to 4.49 3 1023 mol ratio
(2.41 6 0.81 3 1023 mol ratio; Fig. 9).
Hyaluronate
Serum hyaluronate (HA) levels were measured in 58 HD
patients. The mean HA level was high at 241 6 193 ng/ml,
and ranged from 16 to 770 ng/ml. A comparative study of
serum HA and CML-Hb levels showed a highly significant
correlation (r 5 0.434, P , 0.001; Fig. 10).
DISCUSSION
The pathomechanism of dialysis-related amyloidosis has
yet to be clarified, despite numerous studies over the years
since Gejyo et al’s report in 1985 identifying b2m as the key
molecule in the development of dialysis-related amyloidosis
[23]. Current research based on a new concept of protein
glycation is, however, anticipated to provide a potential
breakthrough by identifying the missing link between b2m
and the clinical onset of dialysis-related amyloidosis.
Miyata et al detected pentosidine as the most prevalent
AGE molecule in amyloid tissue removed from dialysis
patients [24]. Subsequently, Niwa et al identified CML-
modified b2m in the amyloid tissue of dialysis-related
amyloidosis patients [12]. It has been reported that dialysis
patients have higher levels of circulating AGE than diabetic
patients, and that in this form the level is independent of
blood glucose concentrations [17, 25]. In addition, a re-
markable increase in a late phase product of the Maillard
reaction, 3-deoxy glucosone (3-DG), is reported to be
associated with an elevation of serum pentosidine in hemo-
dialysis patients [26, 27]. 3-DG has been reported to be
sufficiently reactive to facilitate the formation of AGE-
BSA [28] and AGE-modified b2m [26] by approximately 20
times more than glucose in vitro.
Several in vitro studies have revealed the existence of a
radical molecule to be essential for CML production, and
found that this molecule generates a reactive }-dicarbonyl
intermediate protein, glyoxal [5, 6].
Like 3-DG, glyoxal is highly reactive, thereby greatly
enhancing the production of CML in BSA [5] or RNase [7,
29] compared to glucose in vitro. Fu et al reported that
glyoxal could be generated in an autoxidative reaction of
low density lipoprotein (LDL), and speculated that LDL
might be a major source of CML protein in vivo [29]. In
addition, Dunn et al reported that an oxidative reaction of
ascorbic acid also resulted in CML production [30]. Be-
cause oxidation of LDL failed to produce pentosidine [29]
and CML production from arachidonate was about 25-fold
greater than that from glucose, the size of the metabolic
pool of CML in vivo is suggested to be far larger than that
of pentosidine. These findings raise the possibility that
CML could be detected in quantities sufficient to be a
biomarker of oxidative stress in the clinical setting, partic-
ularly in patients with a long standing exposure to the
stress, such as with maintenance hemodialysis [31–33]. We
found no report other than Degenhardt et al [34] and
Schleicher et al [35] regarding the circulating level of
CML-protein.
Degenhardt et al reported a good correlation between
the serum level of CML measured by GC-MS and AGE
assayed by competitive ELISA, and demonstrated a two-
fold higher CML level in hemodialysis patients than in
healthy controls. Unfortunately, because only five hemodi-
alysis cases were included in their report, we cannot
compare their CML data with those of our study. Schlei-
cher et al measured CML-protein in various human spec-
imens including serum by competitive ELISA using an
anti-CML serum prepared by Bayne’s method, which is
similar to the method used in our study. They reported the
serum level of CML-protein to be 7.3 pmol/mg protein in
normal individuals and 11.6 pmol/mg protein in diabetic
Fig. 9. The relationship between circulating level of CML-Hb and serum
value of methylguanidine over creatinine ratio (MG/Cr) in CRF patients
(E, N 5 7) and HD patients (F, N 5 70). A weakly significant correlation
was recognized in all 77 cases (r 5 0.318, P , 0.01).
Fig. 10. Correlation between circulating level of carboxymethylated he-
moglobin (CML-Hb) and serum value of hyaluronate (HA) in 58 hemo-
dialysis patient (r 5 0.434, P < 0.001).
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patients, and noted a two- or threefold increase in uremic
serum [34, 35], which is compatible with our present data.
Our data on CML-Hb were far higher compared to the
values of serum CML protein in Schleicher’s data. A much
longer half-life of Hb than serum protein might be partially
responsible for this discrepancy, but it is clear there is more
to be elucidated.
To date, investigative analyses of circulating CML-pro-
tein levels in relation to clinical characteristics of dialysis-
related amyloidosis have not been reported. Accordingly,
the present data demonstrating a correlation between the
clinical features of dialysis-related amyloidosis must be
await confirmation in further investigations. However, the
correlation with one of the oxidative stress markers, MG/Cr
[36, 37], proves CML-Hb to be of clinical importance in
development of complications in the setting of long-stand-
ing oxidative stress, including dialysis-related amyloidosis.
There is also a high correlation with HA, a marker of
arthropathy [38, 39] that is a well known characteristic
feature of dialysis-related amyloidosis, further supports this
concept. In addition, the comparison of CML levels with
amyloid score is of paticular interest. On the one hand,
Figure 8 shows a significant difference in CML-Hb level
between dialysis-related amyloidosis negative and positive
patients. On the other hand, no significant difference could
be found between the low amyloid score and high amyloid
score patients. Based on these results, we speculate that
carboxymethylation of protein may participate in the incip-
ient stage rather than progressive stage in the development
of dialysis-related amyloidosis. This assumption may be
overly speculative, however, because our present data are
based solely on one cross sectional study.
Finally, the marked variability in CML-Hb observed
among patients is noteworthy. Contrary to the very exag-
gerated increases in 3-DG and pentosidine, the increases in
circulating levels of CML-protein were rather conservative,
with several patient levels in the same range as that for
healthy individuals. As many as 26 (37.1%) of 70 patients
had relatively low CML-Hb levels, that is, below the upper
limit (mean 6 2 SD) in healthy individuals, and even 15
patients out of 46 patients who were undergoing hemodi-
alysis for more than 10 years did not show a definite
increase in their CML-Hb levels. What is more, the result
in DSA was negative also.
At present, our knowledge about CML in vivo is insuffi-
cient to account for these paradoxical data, that is, the
dissociation of the CML-Hb level and the development of
dialysis-related amyloidosis. It is well known that various
mechanisms counteracting oxidative stress function in vivo
and the functional ability varies not only from state to state,
but also from patient to patient.
As a consequence, variability in the severity and persis-
tence of oxidative stress would result in a broad range of
CML-Hb levels, the potential biomarker of overall inte-
grated oxidative stress. Development of dialysis-related
amyloidosis generally was likely to depend on the length of
dialysis therapy, but we occasionally encountered an un-
likely case in whom the onset was early and severity
marked. Very recently, in examining the onset of definite
clinical signs related to dialysis-related amyloidosis, van
Ypersele de Strihou and colleagues reported earlier
changes of histological evidence [40]. Therefore, to verify
the significance of carboxymethylation of protein in the
pathogenesis of dialysis-related amyloidosis, a longitudinal
study on CML-Hb over several years should be conducted.
Furthermore, to refine the variations in the circulating
CML-protein levels more accurately, a more available assay
system is strongly suggested, for example, an ELISA by a
monoclonal antibody with a higher affinity for CML. This is
being researched now in our laboratory.
Reprint requests to Yoshihiro Motomiya, M.D., Suiyukai Clinic, 676-1,
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APPENDIX
Abbreviations used in this article are: AGE, advanced glycation end
product; b2m, b2-microglobulin; BSA, bovine serum albumin; CML,
carboxymethyllysine or Ne-(carboxymethyl)lysine; CM-polylysine, car-
boxymethylated polylysine; Cr, creatinine; CRF, chronic renal failure;
CTS, carpal tunnel syndrome; 3-DG, 3-deoxy glucosone; DSA, destructive
spondyloarthropathy; HA, hyaluronate; Hb, hemoglobin; HD, hemodial-
ysis; HSA, human serum albumin; LDL, low density lipoprotein; MG,
methylguanidine; MRI, magnetic resonance imaging; PBS, phosphate
buffered saline; PVDF, polyvinylidene difuluoride; SBPA, sandwich bind-
ing protein assay; SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel
electrophoresis.
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